AccuVein, Inc.Medical imaging technology
Alliance Pharma plcLegacy pharmaceutical products
Ambio Holdings, Inc.Peptide pharmaceuticals 
Biotheranostics, Inc.Cancer diagnostics
Cheetah Medical, Inc.Non-invasive haemodynamic monitoring
eZono AGPortable ultrasound
Onbone OyMedical Devices
Patient Connect LimitedPharmacy intervention
Providence Medical Technology, Inc.Cervical Spine Fusion
Valneva SECommercial stage vaccines
Vertos Medical, Inc.Lumbar Spinal Stenosis Devices
Vital Connect, Inc.Wireless Vital Sign Monitoring
ZipLine Medical, Inc.Post-surgical wound closure devices
Portfolio
MVM invests in leading and innovative healthcare companies. Our active portfolio companies are transforming the delivery of healthcare by enabling higher quality yet cost-effective care for the global markets. We strive to maintain a focused portfolio, concentrating our efforts towards building truly world-class companies.
Recent News
Alliance Pharma acquires Nizoral rights in APAC region
Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, is pleased to announce that it has agreed to acquire exclusive marketing rights to Nizoral, a medical, anti-dandruff shampoo brand, in Asia-Pacific from Janssen Pharmaceutica NV.
Alliance Pharma receives positive opinion for Diclectin
Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, announces that, following discussions with the Medicines and Healthcare products Regulatory Agency and the Commission on Human Medicines, the Marketing Authorisation Application for Diclectin® is now considered approvable.